Cortexin for pediatric speech-development disorders: phase III trial GP20061-P4-03-01
GEROPHARM · 2025 · Russian trial authorization No. 77, protocol GP20061-P4-03-01.
Reported findings and study design
No measured outcomes in the accessed disclosure
Phase III, multicenter, randomized, double-blind and placebo-controlled.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Efficacy and safety | No public results located. The registry records the design and listed sample. |
Source for these results ↗ · Reviewed 2026-11-10
For research and education. Consult a qualified clinician for medical advice.
Study limitations and source details
Study limitations
- The registered population has speech-development disorders. The registration contains no clinical effect or safety estimate.
Source access
Trial registration and listed dates checked. The registry count does not verify actual enrollment or completion.
Source reviewed 2026-11-10.
Source type: Trial registration
Citation and original source
Original source: GEROPHARM. Cortexin for pediatric speech-development disorders: phase III trial GP20061-P4-03-01 Russian trial authorization No. 77, protocol GP20061-P4-03-01. 2025.
Molekul research summary: https://molekul.io/research/cortexin-speech-rectal-phase3-2025. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry